Managing Variations in the EU Regulatory System
In the European Union (EU), obtaining a marketing authorization for a medicinal product is not the end of the regulatory journey—it marks the beginning of continuous lifecycle management.…
Insights
56 articles
In the European Union (EU), obtaining a marketing authorization for a medicinal product is not the end of the regulatory journey—it marks the beginning of continuous lifecycle management.…
The Pharmacovigilance System Master File (PSMF) is a cornerstone of an effective pharmacovigilance (PV) system. It provides a comprehensive and up-to-date description of how a Marketing Authorization Holder…
Pharmacovigilance (PV) is a cornerstone of patient safety and regulatory compliance. While timely processing of Individual Case Safety Reports (ICSRs) is a regulatory requirement, prioritizing speed over accuracy…
Corrective and Preventive Action (CAPA) management is one of the most critical pillars of an effective pharmacovigilance (PV) system. Regulatory inspections—whether conducted by local health authorities or global…
Managing safety signals in rare diseases presents unique and complex challenges for pharmacovigilance (PV) systems worldwide. Limited patient populations, scarce clinical data, and heterogeneous disease presentations often make…
In pharmacovigilance (PV), the accuracy and integrity of safety data are fundamental to protecting patient health and ensuring regulatory compliance. One critical yet sometimes underestimated activity is duplicate…
In pharmacovigilance (PV), data is the foundation of all safety-related decisions. From individual case safety reports (ICSRs) to aggregate safety evaluations, regulatory actions, and benefit–risk assessments, the reliability…
In pharmacovigilance (PV), ensuring patient safety and regulatory compliance depends on robust oversight mechanisms. Two of the most critical oversight activities are pharmacovigilance inspections and pharmacovigilance audits. Although…
As pharmaceutical companies expand into global markets, pharmacovigilance (PV) systems become increasingly complex. While global PV frameworks provide consistency and oversight, patient safety is ultimately safeguarded at the…
Under the EU Good Pharmacovigilance Practices (GVP), Marketing Authorization Holders (MAHs) are required to maintain a fully functioning, compliant, and continuously monitored Pharmacovigilance (PV) system. To achieve this,…
Informative Introduction Effective communication is the backbone of a successful Pharmacovigilance (PV) system. Whether managing safety data, coordinating with vendors, supporting clients, or responding to competent authorities, clear…
Pharmacovigilance (PV) inspections are critical checkpoints in ensuring the safety of medicines and the integrity of post-marketing surveillance systems. Conducted by regulatory authorities and national competent authorities, these…
A Pharmacovigilance Agreement is a legally binding document that clearly defines how safety information will be collected, assessed, exchanged, and reported between partners throughout the product’s life cycle.…
In recent years, the significance of pharmacovigilance (PV) has grown dramatically, and the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates (UAE) has reinforced its…
Pharmacovigilance (PV) in the United States plays a crucial role in ensuring the ongoing safety and efficacy of medicinal products. Unlike the European Union, where Good Pharmacovigilance Practices…
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.